A next-generation T cell therapy platform that redirects the TCR/CD3 complex to overcome key limitations of conventional CAR-T and TCR-T therapies, delivering robust, sustained, and safer immune responses against solid tumors.

An AI-powered high-throughput platform that rapidly discovers therapeutic TCRs by integrating single-cell transcriptomic and functional analysis, significantly cutting time and cost in TCR-based drug development.

An advanced cell armoring platform that enhances ACT therapies by equipping them to overcome TME barriers and heterogeneity, improving safety, infiltration, and persistence in solid tumors.

Industrialized production of GMP-grade vectors and engineered immune cells are the basis for clinical development of immune cell therapy. The Chongqing site was launched in 2017, and the facilities in LA and Guangzhou were launched in 2019 and 2020, respectively.